Bicycle Therapeutics/$BCYC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Ticker

$BCYC
Primary listing

Industry

Biotechnology

Employees

305

ISIN

US0887861088

BCYC Metrics

BasicAdvanced
$497M
-
-$3.13
1.41
-

What the Analysts think about BCYC

Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.

Bulls say / Bears say

Bicycle Therapeutics secured approximately $555 million through a PIPE financing agreement in May 2024, significantly strengthening its cash position and extending its financial runway into the second half of 2027. (nasdaq.com)
The company has multiple collaborations with pharmaceutical giants like Bayer, Novartis, and Roche, leveraging its proprietary platform to develop novel drugs across various indications. (nasdaq.com)
Bicycle Therapeutics' lead candidate, zelenectide pevedotin, is progressing in the registrational Phase II/III Duravelo-2 study for treating metastatic urothelial cancer, indicating potential for significant clinical advancements. (nasdaq.com)
In December 2024, B. Riley lowered its price target for Bicycle Therapeutics from $28.00 to $17.00, reflecting concerns about the company's valuation and future prospects. (defenseworld.net)
The company's stock reached a 52-week low of $14.81 in December 2024, indicating potential investor concerns and market volatility. (investing.com)
Insider selling activity, including the sale of 6,256 shares by CAO Travis Alvin Thompson in November 2024, may raise questions about internal confidence in the company's future performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BCYC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BCYC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCYC

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs